why choose us

First received: July 25, 2023

Clinical Trial: A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cancer

Study Type: INTERVENTIONAL


Official Title: An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refract

Brief Summary: This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Read more